Carter, Anthony ( 2021 )


Menu:
  •            IN THE COURT OF CRIMINAL APPEALS
    OF TEXAS
    NO. PD-0575-19
    ANTHONY CARTER, Appellant
    v.
    THE STATE OF TEXAS
    ON APPELLANT’S PETITION FOR DISCRETIONARY REVIEW
    FROM THE SEVENTH COURT OF APPEALS
    LUBBOCK COUNTY
    YEARY, J., delivered the unanimous opinion of the Court.
    OPINION
    In November of 2017, a jury found Anthony Carter, Appellant, guilty of possession
    of a Penalty Group 2-A controlled substance, with intent to deliver. He was subsequently
    sentenced to 90 years in prison and received a $100,000 fine. The Seventh Court of Appeals
    affirmed his conviction. Carter v. State, 
    575 S.W.3d 892
     (Tex. App.—Amarillo 2019). We
    granted Appellant’s petition for discretionary review to determine whether, in a legal
    sufficiency analysis, a reviewing court may uphold a conviction if expert testimony as to
    CARTER — 2
    certain technical elements of an offense is merely conclusory. Having concluded that the
    testimony in this case is not merely conclusory, we affirm.
    THE STATUTE
    Under Section 481.113 of the Texas Health and Safety Code, a person commits an
    offense if he “knowingly manufactures, delivers, or possesses with intent to deliver a
    controlled substance listed in Penalty Group 2 or 2-A.” TEX. HEALTH & SAFETY CODE §
    481.113(a). That part of the statute is simple enough to understand. But Section
    481.1031(b), the part of the Health and Safety Code describing Penalty Group 2-A gets a
    bit more scientifically esoteric. It was first promulgated in 2011 to address synthetic
    substances, and such substances were originally identified specifically by name. See Acts
    2011, 82nd Leg., ch. 170, eff. Sept. 1, 2011 (enacting TEX. HEALTH & SAFETY CODE §
    481.1031). But in 2015, the Legislature amended Section 481.1031, so that it now defines
    synthetic controlled substances by structural class. See TEX. HEALTH & SAFETY CODE §
    481.1031(b). It appears that one of the reasons for the adoption of the amendment was that
    under the pre-amendment language, “a skilled chemist may [have] be[en] able to change
    the chemical makeup of a substance enough to circumvent the law and make the law
    difficult to enforce.” 1 S. Comm. on Crim. Justice, Bill Analysis, Tex. S.B. 173, 84th Leg.,
    R.S. (2015).
    Accordingly, Penalty Group 2-A, as now defined in Section 481.1031(b), focuses
    on the positioning of certain molecular components to determine whether the synthetic
    1
    The jury in Appellant’s case heard testimony from the State’s expert about the 2015 amendment
    and the different way in which the amended statute defined prohibited synthetic substances.
    CARTER — 3
    compound is prohibited. For example, Subparagraph (5) of Section 481.1031(b), which is
    at issue in this case, describes a “structural class” as “any compound containing a core
    component substituted at the 1-position to any extent, and substituted at the 3-position with
    a link component attached to a group A component, whether or not the core component or
    group A component are further substituted to any extent[.]” TEX. HEALTH & SAFETY CODE
    § 481.1031(b)(5). 2
    THE STANDARD
    When reviewing the legal sufficiency of the evidence, an appellate court must view
    the evidence in the light most favorable to the prosecution and ask whether any rational
    trier of fact could have found each element of the offense beyond a reasonable doubt.
    Johnson v. State, 
    560 S.W.3d 224
    , 226 (Tex. Crim. App. 2018) (citing Jackson v. Virginia,
    
    443 U.S. 307
    , 319 (1979)). The appellate court must give deference to “the responsibility
    of the trier of fact fairly to resolve conflicts in the testimony, to weigh the evidence, and to
    2
    The relevant portions of the statute are as follows:
    (b) Penalty Group 2-A consists of any material, compound, mixture, or
    preparation that contains any quantity of a natural or synthetic chemical substance,
    including its salts, isomers, and salts of isomers, listed by name in this subsection
    or contained within one of the structural classes defined in this subsection:
    * * *
    (5) any compound containing a core component substituted
    at the 1-position to any extent, and substituted at the 3-position with
    a link component attached to a group A component, whether or not
    the core component or group A component are further substituted to
    any extent, including . . .
    TEX. HEALTH & SAFETY CODE § 481.1031(b)(5).
    CARTER — 4
    draw reasonable inferences from basic facts to ultimate facts.” Jackson, 
    443 U.S. at 319
    .
    Circumstantial evidence and direct evidence are equally probative, and either one alone
    can be sufficient to establish guilt. Hooper v. State, 
    214 S.W.3d 9
    , 13 (Tex. Crim. App.
    2007). Juries are permitted to draw reasonable inferences from the evidence presented at
    trial “as long as each inference is supported by the evidence presented at trial.” 
    Id. at 15
    .
    Further, “criminal statutes outside the penal code must be construed strictly, with any doubt
    resolved in favor of the accused.” State v. Johnson, 
    219 S.W.3d 386
    , 388 (Tex. Crim. App.
    2007). Thus, for the court of appeals to have properly affirmed Appellant’s conviction,
    there must have been sufficient evidence presented by the State that the molecular
    components within the compound were positioned as described in Section 481.1031(b)(5).
    The court of appeals concluded that there was, and we agree.
    FACTS AND PROCEDURAL POSTURE
    The facts are undisputed. Appellant operated a handful of smoke shops located in
    Lubbock county. He sold various products, including a leafy substance called “Chilly
    Willy.” In 2014, Appellant received a letter from the Lubbock County District Attorney
    warning him against the continued sale of synthetic marijuana. After receiving the letter,
    Appellant sent samples of his products, including Chilly Willy, to a lab for testing. At that
    time, the Chilly Willy was not tested for fluoro-ADB. However, later testing by the State
    determined that Chilly Willy did, in fact, contain fluoro-ADB.
    Some two years after the 2015 amendment to Section 481.1031(b), the Lubbock
    Police Department executed a search warrant (one of several executed between 2014 and
    2017) at Appellant’s residence. The police found multiple boxes containing individually
    CARTER — 5
    packaged bags of Chilly Willy. Appellant was charged by indictment with “knowingly
    possess[ing], with intent to deliver, ‘Chilly Willy; 2g Chronic Hypnotic’ which contains a
    compound controlled in Penalty Group 2-A, Chapter 481.1031(b)(5) of the Texas Health
    and Safety Code, to wit: fluoro-ADB, by aggregate weight including adulterants and
    dilutants 400 grams or more.”
    At trial, the State presented expert testimony from John Keinath, a controlled
    substance analyst with the Texas Department of Public Safety (DPS) Crime Laboratory in
    Lubbock. Keinath testified that he had been a forensic chemist in the DPS crime lab in
    Lubbock for four years. His expertise included controlled substance and blood analysis. He
    testified that he obtained a Bachelor of Science degree in Forensic Chemistry from Lake
    Superior State University in Michigan and a Master of Science degree in Forensic Science
    from the University of Illinois at Chicago. He testified that he has had an additional four
    months of “intensive” training in analysis of controlled substances through DPS and that
    he is a member of the American Academy of Forensic Sciences. He claimed to have
    testified about twenty times in court about controlled substance or blood analysis.
    Keinath began his testimony with a discussion of Section 481.1031(b) before it was
    amended and the effect of the 2015 amendments. Specifically, Keinath told the jury:
    “[I]nstead of listing each substance by name, we now actually classify a synthetic
    compound by the structure. So there are a whole bunch of different combinations of
    structures, and depending on what kinds of groups create that molecule, it’s classified by
    different subsections in the law.” Keinath went on to testify about the lab’s method of
    testing and how he tested the Chilly Willy substance. He went into painstaking detail about
    CARTER — 6
    the method of testing that he used, and in response to the prosecutor’s question of what
    synthetic compound was contained in the Chilly Willy products, Keinath said, “So – again,
    based off of the 12 [samples] that I tested, the substance contained was fluoro-ADB.”
    Further, Keinath went on to describe the “three parts” needed to determine whether
    the substance falls within Penalty Group 2-A. To help illustrate his point, the State used a
    demonstrative exhibit that depicted fluoro-ADB. We have reproduced that exhibit here:
    Keinath explained the following:
    So how the law is written, we’re looking at what’s called a core component,
    a group A component, and a link component. Up there on the screen, those
    are all the core components that could possibly create a particular substance;
    likewise, with a group A and link components. Now, with any synthetic
    compound, you can take any of those core components, group A components,
    and link components, and make quite a few different structures. But by doing
    so, it changes what the structure is called or what it is named.
    CARTER — 7
    He went on to explain that fluoro-ADB contains various prohibited components in the core
    component, group A component, and the link component. 3 Specifically, he testified that
    the core component of fluoro-ADB was indazole, the group A component contained
    methoxy dimethyl oxobutane, and the link component contained carboxamide. The
    prosecutor then asked Keinath, “So if we put all of those together, then that’s what we see
    here. We see the portions of fluoro-ADB that are relevant to this; is that correct?” To which
    Keinath responded, “Correct. Based off of those three combinations, that’s why [fluoro-
    ADB] is able to be controlled under the structural class with how the law is currently
    written.”
    Also, defense counsel’s own line of questioning on cross-examination helped shed
    some light for the jury. Counsel for the defense asked Keinath: “[Y]’all spent a lot of time,
    [the prosecutor] and you, on how the chemical compounds work with the placement of the
    . . . molecules [and] where the molecules are. And that’s what makes a compound, the place
    where the molecules are stuck, correct?” To which Keinath responded: “Correct.” As cross-
    3
    Section 481.1031(a), subsections (1) through (3), identify, by name, the components that are
    prohibited in the “Core component,” “Group A component” and “Link component.” As relevant
    in this case, they are:
    (a) In this section:
    (1) “Core component” is one of the following: . . ., indazole[.]
    (2) “Group A component” is one of the following: . . ., methoxy dimethyl
    oxobutane[.]
    (3) “Link component” is one of the following functional groups: carboxamide[.]
    TEX. HEALTH & SAFETY CODE § 481.1031(a)(1)‒(3).
    CARTER — 8
    examination continued, defense counsel asked Keinath whether fluoro-ADB is actually
    listed in the statute, and Keinath responded that it is not, but that it is a synthetic compound.
    Keinath went on to explain: “[B]ased off my knowledge, there might be different isomers,
    but as far as the core, the group A, and the link, fluoro-ADB is that particular part of it.”
    Finally, defense counsel spent some time discussing with Keinath types of
    chemicals that also have fluoro-ADB in the name of the chemical. During this colloquy,
    the following exchange occurred:
    Q: And what is 5 fluoro-ADB metabolite 7?
    A: Just based off of the name, all I can really say or infer is that it
    might have something to do with the toxicology of it, so after it’s been
    processed through the system. But I personally don’t know what the “ADB
    metabolite 7” is.
    Q: Do you know if that particular chemical structure is in the Penal
    Code?
    A: Based off of the structure provided on this particular product insert,
    it appears to be the same structure as the 5-fluoro-ADB.
    Q: Okay. What about 2-fluoro-ADB? Are you certain that’s in the
    Penal Code?
    A: The 2-fluoro-ADB would be in the Penal Code, because again,
    based off of the Penal Code, we are looking at the core, the group A, and the
    link. It doesn’t matter where the fluorine falls because the law broadly says
    that if it’s a natural or synthetic compound, it includes any isomers, or
    stereoisomers, any of those. So under the broadness of the Penalty Group 2-
    A law, any sort of isomer would be covered.
    During his testimony Keinath never explicitly described the specific placement of
    the components within the synthetic compound, fluoro-ADB, that Appellant was alleged
    to have possessed in the form of Chilly Willy. Nor did the State present any other evidence
    CARTER — 9
    specifically indicating that indazole (the core component) was substituted at the 1- position
    to any extent, and substituted at the 3- position with carboxamide (the link component)
    attached to methoxy dimethyl oxobutane (the group A component)―as Section
    481.1031(b)(5) requires to establish the existence of a synthetic compound.
    Appellant contended on direct appeal that, because the State produced no explicit
    testimony regarding the exact positioning of the components within fluoro-ABD, the court
    of appeals erred in finding that the evidence was legally sufficient. He argued that an
    ordinary jury could not have taken Keinath’s testimony about the mere presence of the
    components of the compound fluoro-ABD and inferred from that testimony that fluoro-
    ADB satisfied the requisite structural requirements as set out in Section 481.1031(b)(5).
    Accordingly, he argued that the State failed to prove that: “1) he knowingly sold a
    controlled substance listed in [Section] 481.1031(b)(5)[,] and 2) the substance he was
    convicted of possessing fell within that provision.” Carter, 575 S.W.3d at 896. The court
    of appeals disagreed and affirmed Appellant’s conviction, concluding that “[t]he State
    presented sufficient evidence to permit the jury to rationally conclude, beyond reasonable
    doubt, that fluoro-ADB was a controlled substance within the scope of [Section]
    481.103(b)(5).” Id. at 899.
    ANALYSIS
    We conclude that, when looking at all of Keinath’s testimony, a rational trier of fact
    could reasonably infer that his analysis established that fluoro-ADB satisfied the criteria of
    Section 481.1031(b)(5): that indazole (the core component) was substituted at the 1-
    position to any extent, and substituted at the 3-position with carboxamide (the link
    CARTER — 10
    component) attached to methoxy dimethyl oxobutane (the group A component)―even
    though he did not explicitly say so.
    At first glance, it seems irrational to expect an ordinary factfinder to make an
    inference regarding positioning of certain components in a synthetic compound. But, the
    mere fact that an ordinary factfinder, prior to any evidence being presented, could not make
    the required inferential step, does not mean that an informed factfinder could not
    reasonably make such an inference. That is all to say that an ordinary jury could still draw
    a reasonable inference from an expert’s testimony about technical elements as long as each
    inference is supported by the evidence presented at trial. And the jury’s inference here that
    the components were positioned according to the requirements of Section 481.1031(b)(5)
    is supported by the evidence.
    The jury heard three categories of testimony from Keinath: (1) that the statute, as
    amended in 2015, defines prohibited synthetic compounds based on their structure; (2) that
    the Chilly Willy that Appellant possessed contained fluoro-ADB; and (3) that fluoro-ADB
    is prohibited under the statute based on the specific components it possesses and how it is
    structured. Keinath informed the jury about the amended statute and about the listed
    components that make the synthetic compound illegal. He also informed the jury that
    fluoro-ADB contained indazole, carboxamide, and methoxy dimethyl oxobutane. Keinath
    went on to give his ultimate opinion that, “[b]ased off of those three combinations, that’s
    why [fluoro-ADB] is able to be controlled under the structural class with how the law is
    currently written.”
    CARTER — 11
    From the totality of Keinath’s testimony, the jury was adequately informed of the
    fact that fluoro-ADB contains components that are prohibited by Section 481.1031(b)(5).
    Defense counsel’s cross-examination also helped give context to the jury when he asked
    Keinath: “And that’s what makes a compound, the place where the molecules are stuck,
    correct?” When Keinath answered that question with, “Correct,” he was essentially telling
    the jury that what makes a synthetic compound, under the statute, is the molecular
    positioning of those components. Moreover, the jury heard Keinath’s expert conclusion
    that fluoro-ADB does satisfy the criteria for a synthetic controlled substance as defined by
    Section 481.1031(b)(5).
    From these premises, a rational jury could reasonably deduce that Keinath had
    examined the molecular structure of the fluoro-ADB, and had determined it to be a Penalty
    Group 2-A compound precisely because he found that the indazole (the core component)
    was substituted at the 1- position to any extent, and that it was substituted at the 3- position
    with carboxamide (the link component) attached to methoxy dimethyl oxobutane (the
    Group A component). The jury was informed by Keinath during both his direct and cross-
    examination about what the statute prohibits. He also testified to his ultimate conclusion
    that fluoro-ADB constitutes a Penalty Group 2-A synthetic controlled substance under
    Section 481.1031(b)(5). A rational jury could therefore draw the reasonable inference that
    the various components that he identified as falling within fluoro-ADB are positioned
    according to the dictates of Section 481.1031(b)(5). Under these circumstances, we agree
    with the court of appeals that the jury could have rationally concluded that Keinath found
    CARTER — 12
    the core components of fluoro-ADB to be positioned according to the requirements of the
    statute.
    CONCLUSION
    We affirm the court of appeals’ judgment that the evidence was legally sufficient
    because the State presented evidence from which the jury could rationally infer that fluoro-
    ADB was structured in such a way as to satisfy Section 481.103(b)(5).
    DELIVERED:                 March 31, 2021
    PUBLISH
    

Document Info

Docket Number: PD-0575-19

Filed Date: 3/31/2021

Precedential Status: Precedential

Modified Date: 4/5/2021